Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,768.00
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.86
(
7.16%
)
Bitcoin
71,363.73
(
-3.49%
)
News Focus
News Focus
Post# of 257255
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122794
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 136145

Tuesday, 01/31/2012 6:59:02 PM

Tuesday, January 31, 2012 6:59:02 PM

Post# of 257255
Quiz (low difficulty): Prevnar 13 is now PFE’s biggest-selling on-patent* drug and is enjoying explosive growth, increasing worldwide sales in 2011 by 50%. However, in 4Q11, specifically, Prevnar 13 sales declined 25% YoY in the US market. What accounts for this disparity?

*Lipitor still has higher sales despite its being off-patent everywhere.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now